The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) hold a median 12-month price target of $34 — +24.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Alamar Biosciences, Inc. (California) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (67): Analysts have, on balance, been raising their forecasts.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ALMR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +24.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | JP Morgan | Maintains | Overweight | $32 → $35 |
| 11 Aug 2026 | Stifel | Maintains | Buy | $28 → $32 |
| 12 May 2026 | JP Morgan | Initiates | Overweight | — |
| 12 May 2026 | JP Morgan | Initiates | Overweight | $30 |
| 12 May 2026 | Leerink Partners | Initiates | Outperform | — |
| 12 May 2026 | Leerink Partners | Initiates | Outperform | $35 |
| 12 May 2026 | Stifel | Initiates | Buy | — |
| 12 May 2026 | Stifel | Initiates | Buy | $28 |
| 12 May 2026 | TD Cowen | Initiates | Buy | — |
| 12 May 2026 | TD Cowen | Initiates | Buy | $30 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ALMR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 8% of US stocks
Cheaper than 13% of US stocks
Cheaper than 95% of US stocks
Higher than 91% of US stocks
Higher than 73% of US stocks
Higher than 17% of US stocks
Higher than 10% of US stocks
Higher than 80% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alamar Biosciences, Inc. (California) has a market value of $2.1B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $84.7M. The latest quarter grew 82.1% year on year.
Net income over the same four quarters: −$49.2M, a −58.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.76.
Free cash flow in the twelve months to 30 June 2026: −$63.2M, after $1.1M of capital spending.
Trailing P/E: −67.2×; forward P/E: −66.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alamar Biosciences, Inc. (California) employs 286 people — $296K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alamar Biosciences, Inc. (California) — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alamar Biosciences announced that it will participate in upcoming investor conferences. The announcement was issued from Fremont, California, on Nov. 4, 2026.
Why it matters — ALMR watchers may note the company’s planned participation in investor conferences.
Seeking Alpha published a transcript of Alamar Biosciences, Inc.’s Q3 2026 earnings call. The provided excerpt contains only the headline and does not include details from the call.
Why it matters — ALMR watchers can note that a Q3 2026 earnings-call transcript is available, though the excerpt provides no business or financial updates.
Alamar Biosciences reported third-quarter revenue growth of 68% year over year, driven by consumables, new instrument placements and a record quarter for TAP services. The company also raised its full-year revenue outlook and announced large-scale collaborations with UK Biobank and GSK.
Why it matters — The update highlights growth drivers, a higher revenue outlook and collaborations that ALMR watchers may track.
A Zacks item examines Alamar’s Q3 2026 results, focusing on key metrics compared with Wall Street estimates and year-ago values. The excerpt does not provide the metric results.
Why it matters — ALMR watchers may find the metrics useful for assessing quarterly performance against estimates and the prior year.
Alamar Biosciences reported financial results for the quarter ended September 30, 2026, and announced that it raised its 2026 revenue guidance.
Why it matters — The quarterly results and updated revenue guidance provide ALMR watchers with new information about the company’s financial performance and outlook.
The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) have a median 12-month price target of $34, with estimates ranging from $31 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Alamar Biosciences, Inc. (California), 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alamar Biosciences, Inc. (California) 2 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Alamar Biosciences, Inc. (California) ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (67 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +24.5% from the last close, and Ticker Nerd's factor model ranks Alamar Biosciences, Inc. (California) 2 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alamar Biosciences, Inc. (California) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $45 over the next 12 months.
Alamar Biosciences Inc. is a proteomics company focused on developing tools for protein biomarker detection and analysis.
The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Alamar Biosciences to Participate in Upcoming Investor Conferences". Alamar Biosciences announced that it will participate in upcoming investor conferences. The announcement was issued from Fremont, California, on Nov. 4, 2026.
Alamar Biosciences Inc. is a proteomics company focused on developing tools for protein biomarker detection and analysis. Its core platform, NULISA technology, supports ultra-sensitive liquid biopsy workflows designed to measure disease-related proteins from small biofluid samples. The company offers instruments, consumables, assays, and related services built around its precision proteomics platform, including the ARGO high-throughput system and NULISAseq and NULISAqpcr assay products. Alamar Biosciences serves research and translational science customers across immunology, neurology, oncology, and other areas of disease research. Its products are used by academic institutions, biopharmaceutical companies, contract research organizations, and service laboratories that need high-plex protein analysis for biomarker discovery and diagnostic development. Based in Fremont, California, Alamar Biosciences plays a specialized role in the life sciences tools market by enabling advanced protein detection for early disease research and clinical innovation.
CEO Dr. Yuling Luo Ph.D. · 286 employees · United States · https://alamarbio.com
